• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients

Debik, Julia Barbara; Euceda, Leslie R.; Lundgren, Steinar; Gythfeldt, Hedda; Garred, Øystein; Borgen, Elin; Engebråten, Olav; Bathen, Tone Frost; Giskeødegård, Guro F.
Journal article, Peer reviewed
Accepted version
Thumbnail
View/Open
Debik_supplementary (517.1Kb)
Debik (783.3Kb)
URI
http://hdl.handle.net/11250/2640460
Date
2019
Metadata
Show full item record
Collections
  • Institutt for klinisk og molekylær medisin [2008]
  • Institutt for sirkulasjon og bildediagnostikk [1013]
  • Publikasjoner fra CRIStin - NTNU [19849]
  • Publikasjoner fra Cristin - St. Olavs hospital [312]
  • St. Olavs hospital [526]
Original version
Journal of Proteome Research. 2019, 18 (10), 3649-3660.   10.1021/acs.jproteome.9b00316
Abstract
Patients with locally advanced breast cancer have a worse prognosis compared to patients with localized tumors and require neoadjuvant treatment before surgery. The aim of this study was to characterize the systemic metabolic effect of neoadjuvant chemotherapy in patients with large primary breast cancers and to relate these changes to treatment response and long-term survival. This study included 132 patients with large primary breast tumors randomized to receive neoadjuvant chemotherapy with or without the addition of the antiangiogenic drug Bevacizumab. Tumor biopsies and serum were collected before and during treatment and, serum additionally 6 weeks after surgery. Samples were analyzed by nuclear magnetic resonance spectroscopy (NMR). Correlation analysis showed low correlations between metabolites measured in cancer tissue and serum. Multilevel partial least squares discriminant analysis (PLS-DA) showed clear changes in serum metabolite levels during treatment (p-values ≤ 0.001), including unfavorable changes in lipid levels. PLS-DA revealed metabolic differences between tissue samples from survivors and nonsurvivors collected 12 weeks into treatment with an accuracy of 72% (p-value = 0.005); however, this was not evident in serum samples. Our results demonstrate a potential clinical application for serum-metabolomics for patient monitoring during and after treatment, and indicate potential for tissue NMR spectroscopy for predicting patient survival.
Publisher
American Chemical Society
Journal
Journal of Proteome Research

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit